Skip to content
Yog Pharma
Respiratory and allergyLeukotriene receptor antagonist

Montelukast Sodium is a leukotriene receptor antagonist indicated for asthma prophylaxis, exercise-induced bronchoconstriction and allergic rhinitis. We supply it to US manufacturers of tablets, chewable tablets and oral granules.

CAS151767-02-1608.2 g/molC35H35ClNNaO3S
2D structure of Montelukast Sodium, shown as the active moiety without counter-ion or water of hydration.

Data from PubChem (CID 23663996) and FDA’s substance registry

CAS number

151767-02-1

Molecular formula

C35H35ClNNaO3S

Molecular weight

608.2g/mol

FDA UNII

IUPAC name

sodium 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetate

InChIKey

LBFBRXGCXUHRJY-HKHDRNBDSA-M

Appearance
Off-white to pale yellow, hygroscopic, optically active powder.
Solubility
Freely soluble in ethanol, methanol and water, and practically insoluble in acetonitrile.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Hygroscopic and sensitive to light, which converts it to the cis-isomer. Ask how it is packed and what limit the source sets for that isomer.

On the US market

Reference product
SingulairNDA 020829
Approved ANDAs
32 with a marketed product
Approved forms and strengths
  • Chewable tablet 4 mg, 5 mg
  • Tablet 10 mg
  • Oral granules 4 mg per packet

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. Strengths of salt forms are stated as the active moiety. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com